Ultragenyx Pharma Q3 Loss Narrows

(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) reported that its third-quarter net loss narrowed to $68.8 million or $1.13 per share, from $113.0 million or $1.96 per share last year.

Quarterly revenues were $81.5 million up from $25.8 million in the previous year. Ultragenyx recognized $37.3 million in total Crysvita revenue in the Ultragenyx territories, which includes $34.1 million in collaboration revenue in the North American profit share territory and net product sales in other regions of $3.3 million.

Analysts polled by Thomson Reuters expected the company to report a loss of $1.27 per share and revenues of $53.89 million for the quarter. Analysts' estimates typically exclude special items.

The lower end of the range for 2020 Crysvita revenue in Ultragenyx territories has been increased to $130.0 million from $125.0 million. The updated guidance range is $130.0 million to $140.0 million.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More